OFIX · XBRL financial data

Orthofix Medical financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OFIX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	406,562	464,479	460,713	746,641	799,491	822,312
Cost of goods and services sold	101,889	114,914	123,544	260,368	253,606	256,295
Gross profit	304,673	349,565	337,169	486,273	545,885	566,017
Research and development	39,056	49,621	49,065	80,231	73,643	65,847
Selling, general and administrative	—	—	308,776	530,395	532,525	554,329
General and administrative	67,948	69,353	79,966	144,659	—	—
Operating income (loss)	(6,266)	(8,315)	(13,268)	(139,110)	(84,619)	(81,428)
Other income (expense)	8,381	(3,343)	(3,150)	(938)	(9,625)	8,106
Income tax expense (benefit)	(2,885)	24,884	2,043	2,716	2,122	1,382
Net income (loss)	2,517	(38,379)	(19,749)	(151,395)	(125,997)	(92,192)
Earnings per share, basic USD per share	0.13	(1.95)	(0.98)	(4.12)	(3.30)	(2.33)
Earnings per share, diluted USD per share	0.13	(1.95)	(0.98)	(4.12)	(3.30)	(2.33)
Weighted average shares, basic thousands of shares	19,268	19,691	20,054	36,729	38,134	39,602
Weighted average shares, diluted thousands of shares	19,392	19,691	20,054	36,729	38,134	39,602

Fiscal years (OFIX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	96,291	87,847	50,700	33,107	83,238	82,025
Accounts receivable	72,423	78,560	82,857	128,098	134,713	135,746
Inventory	84,635	82,974	100,150	222,166	189,452	172,319
Prepaid and other current assets	16,500	20,141	22,283	32,422	23,382	23,667
Total current assets	270,379	269,522	255,990	420,443	433,285	416,847
Property and equipment, net	63,613	59,252	58,229	159,060	139,804	129,399
Right-of-use asset	4,840	3,155	6,788	19,869	17,238	22,279
Goodwill	84,018	71,317	71,317	194,934	194,934	194,934
Total assets	525,861	476,623	458,629	925,315	893,294	850,647
Accounts payable	23,118	26,459	27,598	58,357	48,803	58,392
Accrued liabilities	6,090	7,151	9,611	12,189	11,391	9,857
Current portion of long-term debt	—	—	—	1,250	0	0
Total current liabilities	103,899	105,830	83,624	165,223	168,628	170,482
Long-term debt	—	—	—	93,107	157,015	157,391
Lease liability, non-current	2,946	1,443	5,376	17,125	14,084	25,413
Total liabilities	168,997	139,689	121,769	326,585	390,170	400,610
Retained earnings (accumulated deficit)	59,379	21,000	1,251	(150,144)	(276,141)	(368,333)
Total stockholders' equity	356,864	336,934	336,860	598,730	503,124	450,037
Total liabilities and equity	525,861	476,623	458,629	925,315	893,294	850,647
Common shares outstanding (cover page) thousands of shares	19,512	19,853	36,456	37,407	39,022	40,144

Fiscal years (OFIX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	2,517	(38,379)	(19,749)	(151,395)	(125,997)	(92,192)
Stock-based compensation	16,207	15,432	18,443	35,707	32,455	28,688
Depreciation and amortization	30,546	29,599	29,019	53,063	60,061	77,321
Net cash from operating activities	74,272	18,475	(11,538)	(45,753)	25,790	33,347
Purchases of property and equipment	15,485	17,785	21,364	60,256	—	—
Net cash from investing activities	(52,334)	(23,013)	(24,534)	(33,131)	(27,580)	(34,598)
Proceeds from issuing common stock	7,598	8,824	4,337	5,127	6,257	5,929
Net cash from financing activities	3,245	(3,621)	(78)	65,322	50,709	(786)
Net change in cash	26,418	(8,974)	(37,147)	(12,943)	47,981	(623)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Orthofix Medical	103,810	210,933	(6,224)*	40.7M	16.7 quarters	Q2 FY26 10-QJun 30, 2026
Angiodynamics	33,973	80,915	(15,330)	42.1M	2.2 quarters	Q1 FY27 10-QAug 31, 2026
Axogen	328,888	75,834	16,536*	59.7M	—	Q3 FY26 10-QSep 30, 2026
Delcath Systems	47,521	29,133	5,712*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Ceribell	41,989	29,341	(13,078)*	38.8M	7.8 quarters	Q3 FY26 10-QSep 30, 2026
Iradimed	63,288	24,203	6,997*	12.8M	—	Q3 FY26 10-QSep 30, 2026
Pulse Biosciences	101,620	434	(18,709)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Butterfly Network	122,301	32,598	(2,266)*	not reported	10.3 quarters	Q3 FY26 10-QSep 30, 2026
Orthopediatrics	17,141	72,661	4,506*	26.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.